Before co-founding a biotech startup initialJakob Uszkoreit has an idea that will eventually make generative artificial intelligence possible. as a researcher Google In 2017, Uszkoreit tried to speed up the training of neural networks.
He suggests a new approach to interpreting data called self-focus. This idea gave way to transformers, the neural network architecture that underpins the generation of artificial intelligence.
“There are actually some applications, like at Google and elsewhere, that have deployed Transformer in production a long time ago, but without much fanfare,” Uszkoreit told CNBC in June. OpenAI’s ChatGPT launches in late 2022, he said , “putting these apps in the spotlight.”
The idea for Transformer was published by Uszkoreit and seven other Google researchers in 2017 in Attention Is All You Need Paper. All eight authors have since left Google.
“Maybe Google can’t be as bold as a much smaller company like OpenAI when it comes to applying this technology to a completely different type of product,” Uszkoreit said. “That’s something we fundamentally have to accept, really, from In a sense, maybe even grateful, because Google is giving the world something we rely on every day.”
Inceptive co-founder and CEO Jakob Uszkoreit is committed to using generative artificial intelligence to change the way drugs work
initial
Uszkoreit left Google in 2021 to co-found Inceptive, which he describes as a biosoftware company. September, the beginning of school raised $100 million In a funding round led by Andreessen Horowitz Nvidia Trying to apply artificial intelligence to drug development.
“We started by focusing on RNA, the exact composition of which is designed through generative artificial intelligence, so that these molecules within certain biological systems end up exhibiting behaviors that are intrinsic to those systems,” Uszkoreit said. “In effect, the taste of this drug Works more harmoniously with living systems than most existing drugs.”
watch video Listen to the full conversation between CNBC’s Katie Tarasov and Inceptive CEO Jakob Uszkoreit.
